Kirenol relieves rheumatoid arthritis by targeting the TWEAK/Fn14 pathway.
Uložené v:
| Názov: | Kirenol relieves rheumatoid arthritis by targeting the TWEAK/Fn14 pathway. |
|---|---|
| Autori: | Chen Z; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Wang J; School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China., Xiao L; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Chen Z; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Luo W; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Xu W; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Lin Y; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Huang M; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Zhang Y; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Wang Y; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Chen Y; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China., Nan L; College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China. |
| Zdroj: | International journal of molecular medicine [Int J Mol Med] 2025 Oct; Vol. 56 (4). Date of Electronic Publication: 2025 Jul 19. |
| Spôsob vydávania: | Journal Article |
| Jazyk: | English |
| Informácie o časopise: | Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9810955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-244X (Electronic) Linking ISSN: 11073756 NLM ISO Abbreviation: Int J Mol Med Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Athens, Greece : D.A. Spandidos, [1998- |
| Výrazy zo slovníka MeSH: | Arthritis, Rheumatoid*/drug therapy , Arthritis, Rheumatoid*/metabolism , Arthritis, Rheumatoid*/pathology , Cytokine TWEAK*/metabolism , TWEAK Receptor*/metabolism , Signal Transduction*/drug effects, Animals ; Humans ; Rats ; Arthritis, Experimental/drug therapy ; Arthritis, Experimental/pathology ; Arthritis, Experimental/metabolism ; Synoviocytes/drug effects ; Synoviocytes/metabolism ; Cell Proliferation/drug effects ; Male ; Rats, Sprague-Dawley ; Cell Line ; Synovial Membrane/pathology ; Synovial Membrane/drug effects ; Synovial Membrane/metabolism ; Transforming Growth Factor beta1 |
| Abstrakt: | Fibroblast‑like synoviocytes (FLSs) are the primary drivers of synovial tissue hyperplasia in rheumatoid arthritis (RA). Activation of the tumor necrosis factor‑like weak inducer of apoptosis (TWEAK)/fibroblast growth factor‑inducible immediate‑early response protein 14 (Fn14) pathway significantly contributes to the pathogenesis of RA. Kirenol (Kir), a compound with anti‑inflammatory and antirheumatic properties, has an unclear mechanism of action. To comprehensively investigate the effects and potential mechanisms of Kir on RA, the present study employed both an in vitro model of transforming growth factor‑β1 (TGF‑β1)‑induced human fibroblast‑like MH7A synoviocytes proliferation and an in vivo collagen‑induced arthritis (CIA) rat model. The effects of Kir on synovial fibroblasts were detected via flow cytometry, ELISA, hematoxylin and eosin staining, safranin‑O/fast green staining, immunohistochemistry, immunofluorescence and western blotting. Kir ameliorated pathological damage in the synovial tissue of CIA rats, suppressed rheumatoid factor production, regulated the T helper 17 cells/regulatory T cell balance and mitigated joint inflammation and swelling. Additionally, Kir markedly downregulated the protein levels of the TWEAK/Fn14 pathway in synovial tissue. Surface plasmon resonance demonstrated that Kir could specifically bind to Fn14. Kir significantly suppressed the TGF‑β1‑mediated aberrant proliferation and migration of MH7A cells. However, the overexpression of Fn14 reversed the inhibitory effects of Kir on the abnormal proliferation and migration of cells, as did the activation of the TWEAK/Fn14 pathway. These results suggest that Kir possesses anti‑RA properties by inhibiting abnormal immune‑inflammatory responses, as well as synovial cell proliferation and migration. These effects of Kir may be linked to a decrease in the activity of the TWEAK/Fn14 pathway. |
| References: | Cell Res. 2011 Jan;21(1):71-85. (PMID: 21173796) Eur J Immunol. 2009 Aug;39(8):2040-4. (PMID: 19672892) Curr Rheumatol Rep. 2020 Jun 26;22(8):44. (PMID: 32591916) Front Cell Dev Biol. 2023 Nov 06;11:1267837. (PMID: 38020877) Wiley Interdiscip Rev Syst Biol Med. 2009 Jul-Aug;1(1):107-115. (PMID: 20151024) Nat Rev Rheumatol. 2022 Oct;18(10):591-602. (PMID: 36068354) Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651. (PMID: 20457564) Ann Rheum Dis. 2023 May;82(5):621-629. (PMID: 36627170) Curr Opin Rheumatol. 2024 May 1;36(3):217-224. (PMID: 38411194) Sci Rep. 2023 Sep 11;13(1):14924. (PMID: 37696876) Cytokine. 2017 Jun;94:45-51. (PMID: 28411045) FEBS J. 2008 Sep;275(18):4448-55. (PMID: 18662305) Curr Opin Immunol. 2001 Dec;13(6):670-5. (PMID: 11677088) J Orthop Surg Res. 2022 Apr 1;17(1):195. (PMID: 35365162) J Leukoc Biol. 2012 Aug;92(2):265-79. (PMID: 22672874) Front Pharmacol. 2016 Nov 25;7:447. (PMID: 27932980) Phytother Res. 2022 Sep;36(9):3662-3671. (PMID: 35766233) J Clin Med. 2025 Feb 25;14(5):. (PMID: 40094988) Arthritis Res Ther. 2013;15 Suppl 3:S2. (PMID: 24267197) Nat Immunol. 2021 Jan;22(1):10-18. (PMID: 33257900) Acta Pharmacol Sin. 2020 Jun;41(6):800-812. (PMID: 31937932) Ann Rheum Dis. 2010 Jan;69(1):301-4. (PMID: 19147618) J Pharm Biomed Anal. 2011 Jun 1;55(3):452-7. (PMID: 21411260) Nat Commun. 2022 Feb 1;13(1):608. (PMID: 35105890) Arthritis Res Ther. 2017 Nov 10;19(1):248. (PMID: 29126436) Int Immunopharmacol. 2023 Nov;124(Pt B):110913. (PMID: 37717316) J Ethnopharmacol. 2011 Sep 1;137(1):774-82. (PMID: 21745559) Phytomedicine. 2012 Jul 15;19(10):882-9. (PMID: 22673798) Nat Rev Rheumatol. 2020 Jun;16(6):316-333. (PMID: 32393826) Mol Med Rep. 2022 May;25(5):. (PMID: 35322865) J Ethnopharmacol. 2021 Dec 5;281:114552. (PMID: 34438028) J Immunol. 2003 Dec 15;171(12):6838-45. (PMID: 14662890) Exp Cell Res. 2011 Mar 10;317(5):620-31. (PMID: 21376175) Clin Exp Rheumatol. 2022 Jul;40(7):1420-1431. (PMID: 34874837) Int J Mol Sci. 2021 Feb 09;22(4):. (PMID: 33572320) Cytokine. 2012 Oct;60(1):143-9. (PMID: 22819243) Front Pharmacol. 2019 Feb 12;10:94. (PMID: 30809149) Front Immunol. 2020 Dec 11;11:572858. (PMID: 33362761) Exp Mol Med. 2007 Aug 31;39(4):499-507. (PMID: 17934338) Cells. 2021 Oct 23;10(11):. (PMID: 34831081) Biomed Pharmacother. 2020 Nov;131:110628. (PMID: 32890968) Arthritis Rheumatol. 2016 Jul;68(7):1614-26. (PMID: 26815411) Sci Rep. 2022 Dec 6;12(1):21099. (PMID: 36473902) Front Immunol. 2024 May 08;15:1415672. (PMID: 38779670) Rheumatology (Oxford). 2008 Apr;47(4):442-50. (PMID: 18310134) Front Immunol. 2021 Nov 15;12:790880. (PMID: 34868079) |
| Contributed Indexing: | Keywords: fibroblast growth factor‑inducible immediate‑early response protein 14; kirenol; rheumatoid arthritis; synovial fibroblast; tumor necrosis factor‑like weak inducer of apoptosis |
| Substance Nomenclature: | 0 (Cytokine TWEAK) 0 (TWEAK Receptor) 0 (TNFSF12 protein, human) 0 (TNFRSF12A protein, human) 0 (Transforming Growth Factor beta1) |
| Entry Date(s): | Date Created: 20250719 Date Completed: 20250719 Latest Revision: 20250730 |
| Update Code: | 20250731 |
| PubMed Central ID: | PMC12289127 |
| DOI: | 10.3892/ijmm.2025.5586 |
| PMID: | 40682832 |
| Databáza: | MEDLINE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Fibroblast‑like synoviocytes (FLSs) are the primary drivers of synovial tissue hyperplasia in rheumatoid arthritis (RA). Activation of the tumor necrosis factor‑like weak inducer of apoptosis (TWEAK)/fibroblast growth factor‑inducible immediate‑early response protein 14 (Fn14) pathway significantly contributes to the pathogenesis of RA. Kirenol (Kir), a compound with anti‑inflammatory and antirheumatic properties, has an unclear mechanism of action. To comprehensively investigate the effects and potential mechanisms of Kir on RA, the present study employed both an in vitro model of transforming growth factor‑β1 (TGF‑β1)‑induced human fibroblast‑like MH7A synoviocytes proliferation and an in vivo collagen‑induced arthritis (CIA) rat model. The effects of Kir on synovial fibroblasts were detected via flow cytometry, ELISA, hematoxylin and eosin staining, safranin‑O/fast green staining, immunohistochemistry, immunofluorescence and western blotting. Kir ameliorated pathological damage in the synovial tissue of CIA rats, suppressed rheumatoid factor production, regulated the T helper 17 cells/regulatory T cell balance and mitigated joint inflammation and swelling. Additionally, Kir markedly downregulated the protein levels of the TWEAK/Fn14 pathway in synovial tissue. Surface plasmon resonance demonstrated that Kir could specifically bind to Fn14. Kir significantly suppressed the TGF‑β1‑mediated aberrant proliferation and migration of MH7A cells. However, the overexpression of Fn14 reversed the inhibitory effects of Kir on the abnormal proliferation and migration of cells, as did the activation of the TWEAK/Fn14 pathway. These results suggest that Kir possesses anti‑RA properties by inhibiting abnormal immune‑inflammatory responses, as well as synovial cell proliferation and migration. These effects of Kir may be linked to a decrease in the activity of the TWEAK/Fn14 pathway. |
|---|---|
| ISSN: | 1791-244X |
| DOI: | 10.3892/ijmm.2025.5586 |